Why segregation of rejected or discontinued samples matters:

In any pharmaceutical stability program, there will be cases where batches are rejected due to OOS results, deviations, or regulatory decisions. Similarly, discontinued products may remain under stability study for ongoing data evaluation. Tagging and storing these samples separately prevents mix-ups with approved products, protects data integrity, and enables clean traceability during audits or investigations.

Potential consequences of poor segregation practices:

If rejected samples are stored alongside compliant material without clear identification, it can lead to inadvertent testing, data contamination, or false reporting. This not only compromises the integrity of the stability program but may trigger data integrity observations, warning letters, or internal quality system breakdowns. Regulatory authorities expect complete control over all sample flows—including those no longer under routine study.

Regulatory and Technical Context:

GMP and WHO guidance on rejected materials handling:

WHO TRS 1010, ICH Q1A(R2), and US FDA 21 CFR Part 211 emphasize that rejected or non-conforming materials must be clearly identified and stored separately under controlled access. This includes materials undergoing investigation, under dispute, or awaiting final disposal. The principle of physical and procedural segregation applies equally to stability sample storage as it does to warehouse inventory or QC samples.

Audit and submission expectations:

During audits, inspectors often visit stability chambers and examine whether all stored materials are properly labeled, segregated, and traceable. Any mixing of rejected/discontinued samples with approved product stock can lead to a serious compliance breach. In CTD Module 3.2.P.8.3, regulators may request clarity on which stability data corresponds to ongoing versus terminated studies—making tagging critical for traceability.

Best Practices and Implementation:

Establish robust tagging and documentation procedures:

Clearly label all rejected or discontinued samples with:

• “REJECTED” or “DISCONTINUED” tag with bold, visible marking
• Batch number, rejection reason, and rejection/discontinuation date
• QA authorization signature and decision document reference

Use tamper-evident labels or color-coded tags for quick identification during storage audits or sample pulls.

Designate separate storage zones and controlled access:

Within each stability chamber or controlled storage area, create clearly defined zones or compartments for rejected and discontinued samples. These zones must be marked with signage, locked if necessary, and monitored to prevent accidental access or test inclusion. Restrict physical access through badge control or logbook tracking for high-risk material.

Record movements of these samples in a separate logbook, and update inventory records to reflect their status change.

Incorporate segregation into SOPs and training:

Update your stability, sample handling, and disposal SOPs to include procedures for managing rejected or discontinued material. Define roles and responsibilities for tagging, relocating, and logging such samples. Train personnel on how to distinguish and handle these materials, and include scenarios in mock audit drills or data integrity reviews.

Schedule routine checks to verify that sample segregation procedures are being followed and documented properly.